Clinical Trial Update: Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, and drug levels of BMS-986435/MYK-224 in participants with heart failure with preserved ejection fraction; curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• BMS-986435
• MYK-224

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Heart Failure | Phase 2 | Status: RECRUITING